Applied Precision Cancer Medicine in Neuro-Oncology
暂无分享,去创建一个
[1] A. Matheu,et al. Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges , 2019, Cancers.
[2] A. Klekner,et al. Significance of liquid biopsy in glioblastoma - A review. , 2019, Journal of biotechnology.
[3] Bo Zhang,et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: A report from the Pacific Pediatric Neuro‐Oncology Consortium , 2019, International journal of cancer.
[4] Russell Bonneville,et al. Implementing precision cancer medicine in the genomic era. , 2019, Seminars in cancer biology.
[5] P. Keegan,et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.
[6] C. Brennan,et al. Tracking Tumor Evolution in Glioma through Liquid Biopsies of Cerebrospinal Fluid , 2018, Nature.
[7] Diane D. Liu,et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. , 2018, The Lancet. Oncology.
[8] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.
[9] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[10] M. Cowley,et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma , 2018, British Journal of Cancer.
[11] Juxiang Chen,et al. Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment , 2018, Translational oncology.
[12] C. Grommes,et al. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas , 2017, Journal of Immunotherapy for Cancer.
[13] G. Stoffels,et al. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease , 2017, Oncology reports.
[14] I. König,et al. What is precision medicine? , 2017, European Respiratory Journal.
[15] C. Caeiro,et al. Current Standards of Care in Glioblastoma Therapy , 2017 .
[16] B. Nahed,et al. Liquid biopsy for brain tumors , 2017, Expert review of molecular diagnostics.
[17] Georg Langs,et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space , 2017, Nature Medicine.
[18] S. Halford,et al. ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM) , 2017 .
[19] S. Choi,et al. Molecular Testing of Brain Tumor , 2017, Journal of pathology and translational medicine.
[20] Susan M. Chang,et al. Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. , 2016 .
[21] A. Ghazalpour,et al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies , 2016, Oncotarget.
[22] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[23] Timothy C Ryken,et al. Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.
[24] Michael C. Rusch,et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Buchfelder,et al. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment , 2015, Cancer science.
[26] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[27] N. Iqbal,et al. Imatinib: A Breakthrough of Targeted Therapy in Cancer , 2014, Chemotherapy research and practice.
[28] C. Marosi,et al. Response to imatinib as a function of target kinase expression in recurrent glioblastoma , 2014, SpringerPlus.
[29] K. Aldape,et al. Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.
[30] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[31] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[32] M. Lindström,et al. PDGF and PDGF receptors in glioma , 2012, Upsala journal of medical sciences.
[33] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[35] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Olson,et al. Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life , 2005 .
[37] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[38] S. Devleeschouwer. Current Standards of Care in Glioblastoma Therapy -- Glioblastoma , 2017 .
[39] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[40] J. Olson,et al. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. , 2005, Cancer investigation.
[41] C. Marosi,et al. Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy , 2005, Journal of Neuro-Oncology.